Perrigo Company plc (NYSE:PRGO) Shares Acquired by SG Americas Securities LLC

SG Americas Securities LLC boosted its position in Perrigo Company plc (NYSE:PRGO) by 152.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 67,947 shares of the company’s stock after acquiring an additional 41,079 shares during the quarter. SG Americas Securities LLC’s holdings in Perrigo were worth $1,905,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC lifted its stake in shares of Perrigo by 5.1% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,092,398 shares of the company’s stock valued at $28,402,000 after purchasing an additional 52,696 shares in the last quarter. Rhumbline Advisers lifted its position in Perrigo by 0.4% during the fourth quarter. Rhumbline Advisers now owns 370,085 shares of the company’s stock valued at $9,515,000 after buying an additional 1,549 shares in the last quarter. State of New Jersey Common Pension Fund D grew its stake in Perrigo by 13.5% during the fourth quarter. State of New Jersey Common Pension Fund D now owns 77,062 shares of the company’s stock worth $1,981,000 after buying an additional 9,178 shares during the period. Venturi Wealth Management LLC increased its position in shares of Perrigo by 97.8% in the fourth quarter. Venturi Wealth Management LLC now owns 4,215 shares of the company’s stock worth $108,000 after acquiring an additional 2,084 shares in the last quarter. Finally, Handelsbanken Fonder AB raised its stake in shares of Perrigo by 13.8% in the 4th quarter. Handelsbanken Fonder AB now owns 42,100 shares of the company’s stock valued at $1,082,000 after acquiring an additional 5,100 shares during the period. Hedge funds and other institutional investors own 95.91% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen raised shares of Perrigo from a “hold” rating to a “buy” rating in a research report on Saturday, May 24th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, Perrigo currently has an average rating of “Hold” and a consensus price target of $33.00.

Perrigo Stock Performance

Perrigo stock opened at $26.66 on Monday. The firm has a market capitalization of $3.67 billion, a PE ratio of -22.79 and a beta of 0.46. Perrigo Company plc has a one year low of $23.14 and a one year high of $30.93. The stock’s 50 day moving average price is $26.02 and its 200 day moving average price is $26.11. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.77 and a current ratio of 2.56.

Perrigo (NYSE:PRGO) last posted its earnings results on Wednesday, May 7th. The company reported $0.60 EPS for the quarter, topping analysts’ consensus estimates of $0.56 by $0.04. The business had revenue of $1.04 billion for the quarter, compared to analysts’ expectations of $1.09 billion. Perrigo had a negative net margin of 3.64% and a positive return on equity of 7.38%. The business’s revenue for the quarter was down 3.5% compared to the same quarter last year. During the same period in the previous year, the company posted $0.29 earnings per share. As a group, sell-side analysts expect that Perrigo Company plc will post 2.56 EPS for the current fiscal year.

Perrigo Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 17th. Shareholders of record on Friday, May 30th will be given a $0.29 dividend. The ex-dividend date of this dividend is Friday, May 30th. This represents a $1.16 dividend on an annualized basis and a yield of 4.35%. Perrigo’s payout ratio is currently -88.55%.

Perrigo Company Profile

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.